Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
uPAR PET/CT in Radium-223 Treatment for mCRPC
NCT02964988Phase 2Terminated
- Sponsor
- Rigshospitalet
- Start
- Jan 2017
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Rigshospitalet. Primary endpoints: uPAR PET/CT imaging uptake (SUV) and Change in uPAR PET/CT uptake after two cycles of Radium-223 at 8 weeks. Started Jan 2017; status: terminated.
Beyond the preview
Go deeper on NCT02964988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964988.